📊 ATOS Key Takeaways
Investment Thesis
Atossa Therapeutics is a pre-revenue pharmaceutical company with severe cash burn and negative returns on equity and assets, indicating value destruction. While the company maintains a strong cash position of $51.8M, at a quarterly burn rate of $19.2M in operating cash flow, the runway extends only ~2.7 years without revenue generation. The complete absence of revenue combined with mounting operating losses makes this a high-risk early-stage biotech with unproven commercial viability.
ATOS Strengths
- Strong liquidity position with $51.8M in cash and 6.77x current ratio providing runway for continued R&D
- Minimal debt burden with zero long-term debt and 0.00x debt-to-equity ratio reducing financial distress risk
- Operating expenses remain controlled relative to cash reserves, suggesting disciplined cash management
ATOS Risks
- Zero revenue with $25.7M quarterly operating losses indicates pre-commercial stage with unproven product-market fit
- Negative FCF of $19.2M per quarter limits R&D spending flexibility and creates near-term existential risk if funding unavailable
- Severely negative ROE (-47.9%) and ROA (-41.1%) demonstrate substantial shareholder value destruction and capital inefficiency
- Cash runway of approximately 2.7 years creates near-term dilution risk if additional capital raises required before achieving profitability
Key Metrics to Watch
- Quarterly operating cash burn rate trend and runway to profitability/next capital raise
- Clinical trial progression and regulatory milestone achievements for pipeline drugs
- Cash balance preservation and any equity or debt financing announcements
ATOS Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 6.77x current ratio provides a solid financial cushion.
ATOS Profitability Ratios
ATOS vs Healthcare Sector
How ATOSSA THERAPEUTICS, INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
ATOS Balance Sheet & Liquidity
ATOS 5-Year Financial Trend
5-Year Trend Summary: ATOSSA THERAPEUTICS, INC.'s revenue has declined by 100% over the 5-year period, indicating business contraction. The most recent EPS of $-0.24 indicates the company is currently unprofitable.
ATOS Growth Metrics (YoY)
ATOS Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2016 | N/A | $204.7K | N/A |
| Q2 2016 | N/A | -$1.7M | N/A |
| Q1 2016 | N/A | -$2.3M | N/A |
| Q3 2015 | $3.4K | -$3.2M | N/A |
| Q2 2015 | $9.9K | -$3.1M | N/A |
| Q1 2015 | N/A | -$2.4M | N/A |
| Q3 2014 | N/A | -$3.2M | N/A |
| Q2 2014 | N/A | -$2.6M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ATOS Capital Allocation
ATOS SEC Filings
Access official SEC EDGAR filings for ATOSSA THERAPEUTICS, INC. (CIK: 0001488039)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ATOS
What is the AI rating for ATOS?
ATOSSA THERAPEUTICS, INC. (ATOS) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ATOS's key strengths?
Strong liquidity position with $51.8M in cash and 6.77x current ratio providing runway for continued R&D. Minimal debt burden with zero long-term debt and 0.00x debt-to-equity ratio reducing financial distress risk.
What are the risks of investing in ATOS?
Zero revenue with $25.7M quarterly operating losses indicates pre-commercial stage with unproven product-market fit. Negative FCF of $19.2M per quarter limits R&D spending flexibility and creates near-term existential risk if funding unavailable.
What is ATOS's revenue and growth?
ATOSSA THERAPEUTICS, INC. reported revenue of $0.0.
Does ATOS pay dividends?
ATOSSA THERAPEUTICS, INC. does not currently pay dividends.
Where can I find ATOS SEC filings?
Official SEC filings for ATOSSA THERAPEUTICS, INC. (CIK: 0001488039) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ATOS's EPS?
ATOSSA THERAPEUTICS, INC. has a diluted EPS of $-0.18.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.